JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.
about
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsStructure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinasesModulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode DependentStructure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibitionTYK2 kinase activity is required for functional type I interferon responses in vivoTyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitorsTransforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.Activation of JAK2-V617F by components of heterodimeric cytokine receptorsThe constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617.Evaluating human cancer cell metastasis in zebrafish.Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesHigh Expression of Complement Component 5 (C5) at Tumor Site Associates with Superior Survival in Ewing's Sarcoma Family of Tumour Patients.Molecular insights into regulation of JAK2 in myeloproliferative neoplasmsSomatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia.Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms.Quantification of IGF-1 Receptor May Be Useful in Diagnosing Polycythemia Vera-Suggestion to Be Added to Be One of the Minor CriterionStructural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).JAK1 gene polymorphisms are associated with the outcomes of hepatitis B virus infection, but not with α interferon therapy response in a Han Chinese population.Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disordersErythropoietin and IGF-1 signaling synchronize cell proliferation and maturation during erythropoiesisThe Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenesThe role of Janus kinases in haemopoiesis and haematological malignancy.Identification of somatic JAK1 mutations in patients with acute myeloid leukemia.Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.Elevated Serum Insulin-Like Growth Factor 1 Levels in Patients with Neurological Remission after Traumatic Spinal Cord Injury.The use of structural biology in Janus kinase targeted drug discovery.JAK mutations in high-risk childhood acute lymphoblastic leukemiaPerspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinasesType I insulin-like growth factor receptor signaling in hematological malignancies.Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective.Therapeutic potential of tyrosine kinase 2 in autoimmunity.Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells.Critical role of the platelet-derived growth factor receptor (PDGFR) beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein.The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation
P2860
Q26782539-5325B7F1-C04F-4317-955E-3C67F020525CQ27679885-412354C2-B396-4E9D-B4C8-952C5149EB4CQ27681086-00EF445E-8B6C-4A41-8A78-86B066B1F441Q27683852-9013DF0A-0A8D-469A-A325-1C198668094CQ28728338-A4B1E1B3-E1DB-4906-9F4D-2BBDDB859769Q30385239-C363F4AE-29C0-4CFF-A8D4-1AE563D66E5DQ33419762-EBA33364-A29C-4B59-A53E-5E3F5A5CC48EQ33618917-98F9A087-1228-4C87-A46E-09041A548406Q33702627-3EE945E8-DFA7-4B1C-A4AB-9248C9E0DBE0Q33843072-B99CB36F-543D-4CA0-817B-1F4936EA938AQ33883366-1D9B0355-F657-4C51-A42C-2AF79416FB3AQ34316190-3C3968EA-C285-41F7-8728-9E0CEB7BABC4Q35007082-371F1684-8D9E-4724-BD50-580EA2579532Q35132241-D79FD4CC-D8D9-4D4D-8973-D10902106EAEQ35389934-5DF08201-480E-4A51-AE59-2B7F53BFE342Q35661987-08192429-C485-48D6-998E-7908D3BBACEAQ35744654-B72E7C36-BEBB-40D2-A3F1-4F6E816EB86CQ36153557-D70449C7-65F4-48DD-BBBC-CDEE297D231BQ36182119-9D7E6BF8-F452-4EFD-B7B2-4308F9D4CA65Q36283829-4E70210A-FE44-4A7B-A5A7-5D82E3441191Q36308205-8A7E5EAD-DFA1-439B-AE4D-6F5E3B8EE168Q36374813-09B7B972-6D53-4328-AF84-C0D758D88A96Q36424904-EDE366B9-A9F8-448D-A20A-C17C5633E970Q36508949-237BCA6C-F66D-427C-9D1F-2C92AAA83717Q36527760-38FA92B4-1428-4557-8D4B-F426D202A077Q36591400-28A29906-C5B9-4F85-8709-F6F6D5F95C8FQ36905691-8EE5FD99-4A18-453A-B2FB-950D59E166AAQ36955078-F85CB285-9152-40D6-B1FF-14EF9B327404Q37119280-A29F4689-2597-475C-B233-ECE998497DFFQ37206115-DE4FCC86-206E-48DE-A8FC-DD62D6D84EC2Q37224111-90F655BA-8542-4EA8-B2E7-E213F73C64FFQ37687519-7C9C97D7-7A55-4DCB-9548-37F9C2A3CA48Q37702186-3C588E35-0CA2-43CC-BF8A-96029C2EBF16Q38122238-848A0F5B-6F44-4433-B1C3-7538C769B93BQ38140890-90D54307-EC13-4BB0-99DF-EA719E02E3E0Q38198086-CBAD0F44-8822-4B58-A9D9-750241F47FA7Q38620874-3DEC02CF-7036-407C-949C-2D483F0949A8Q39354039-4BB3271A-D117-49A4-B6EB-AD25EAC78472Q39738130-8592F42D-1D3C-40A7-917A-44D0984E5E31Q39818667-5C16A14B-06F6-4A0B-A970-F92411AB3529
P2860
JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
JAK1 and Tyk2 activation by th ...... cross-talk with IGF1 receptor.
@en
type
label
JAK1 and Tyk2 activation by th ...... cross-talk with IGF1 receptor.
@en
prefLabel
JAK1 and Tyk2 activation by th ...... cross-talk with IGF1 receptor.
@en
P2860
P50
P356
P1476
JAK1 and Tyk2 activation by th ...... cross-talk with IGF1 receptor
@en
P2093
Anders Kallin
Judith Staerk
P2860
P304
41893-41899
P356
10.1074/JBC.C500358200
P407
P577
2005-10-19T00:00:00Z